Company Description
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States.
The company’s lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients.
It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases.
The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018.
Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jun 20, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Andrew Cheng |
Contact Details
Address: 601 Gateway Boulevard, Suite 350 South San Francisco, California 94080 United States | |
| Phone | 650 487 6488 |
| Website | akerotx.com |
Stock Details
| Ticker Symbol | AKRO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001744659 |
| CUSIP Number | 00973Y108 |
| ISIN Number | US00973Y1082 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrew Cheng M.D., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Jonathan M. Young J.D., Ph.D. | Co-Founder, Executive Vice President, Chief Operating Officer and Secretary |
| William R. White J.D. | Executive Vice President, Chief Financial Officer, Treasurer and Head of Corporate Development |
| Scott A. Gangloff | Chief Technical Officer |
| Catriona Yale | Executive Vice President and Chief Development Officer |
| Dr. Timothy Rolph Ph.D. | Co-Founder and Chief Scientific Officer |
| Thomas Ross | Senior Vice President and Head of Legal |
| John J. Schembri | Senior Vice President and Head of Finance |
| Patrick Lamy | Senior Vice President of Commercial Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | 144 | Filing |
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | 8-K | Current Report |
| May 6, 2025 | 144 | Filing |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 7, 2025 | 144 | Filing |
| Feb 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 28, 2025 | 8-K | Current Report |